ABP-671

Phase 2Small molecule

AAtom Therapeutics Co., Ltd

ABP-671 is one of 53 small molecule programs targeting Hyperuricemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperuricemiaActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

HyperuricemiaPhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

Uloric

Takeda

Preclinical

3 4

Sovaldi

Gilead

Preclinical

1 5

Flomax

Epoetin Beta

5 7

ABP-671

AAtom Therapeutics Co., Ltd

Phase 2

1 8

PROCRIT

WWim Janssens

Preclinical

1 9

Genotropin

EMD Serono

Preclinical

1 10

SGLT2 Inhibitor

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Not yet recruiting

Interaction

NCT07367971

Q1 2028

Phase 2Not yet recruiting

Chronic Kidney Disease

NCT07323095

Clinical

Trials by Indication[1]

Tics2 trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

Completed·AAtom Therapeutics Co., Ltd·Phase 1·NCT04060173·27 enrolled

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

Completed·AAtom Therapeutics Co., Ltd·Phase 1·NCT03906006·32 enrolled

Chronic Kidney Disease1 trial

Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

Not yet recruiting·AAtom Therapeutics Co., Ltd·Phase 2·NCT07323095·75 enrolled

Interaction1 trial

Drug-Drug Interaction Study of ABP-671 in Gout Patients

Not yet recruiting·AAtom Therapeutics Co., Ltd·Phase 1·NCT07367971·20 enrolled

Hyperuricemia1 trial

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia

Completed·AAtom Therapeutics Co., Ltd·Phase 2·NCT04638543·60 enrolled

Gout1 trial

Extension Study of ABP-671 in Participants With Gout

Terminated·AAtom Therapeutics Co., Ltd·Phase 2/3·NCT06276556·43 enrolled

2 more indications

Phase 21 trial

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

Completed·AAtom Therapeutics Co., Ltd·Phase 2/3·NCT05818085·300 enrolled

Unspecified1 trial

Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects

Completed·AAtom Therapeutics Co., Ltd·Phase 1·NCT04303039·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for ABP-671. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABP-671 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABP-671. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Atom Therapeutics Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAtom Therapeutics Co., Ltd

ABP-671

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2028

Trials by Indication[1]

Tics2 trials

Chronic Kidney Disease1 trial

Interaction1 trial

Hyperuricemia1 trial

Gout1 trial

Phase 21 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News